StockNews.AI

ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update

StockNews.AI • 1 minute

BIIBINTCABBV
High Materiality10/10

Information

FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior...

Original source

AI Summary

ADMA anticipates approximately $510-$511 million in 2025 total revenue. 2026 expected to be the first year of yield-enhanced ASCENIV production. Strong ASCENIV demand and expansion in payer coverage expected. 2026 total revenue guidance increased to approximately $635 million. ADMA targets over $1.1 billion in annual revenue by FY 2029.

Sentiment Rationale

ADMA's revenues are exceeding projections, and strong future guidance supports growth; similar growth patterns led to rising stock prices previously.

Trading Thesis

With strategic growth plans and increased product demand, ADMA is positioned for sustained revenue and market position expansion into 2029.

Market-Moving

  • ADMA anticipates approximately $510-$511 million in 2025 total revenue.
  • 2026 expected to be the first year of yield-enhanced ASCENIV production.
  • Strong ASCENIV demand and expansion in payer coverage expected.

Key Facts

  • ADMA anticipates approximately $510-$511 million in 2025 total revenue.
  • 2026 expected to be the first year of yield-enhanced ASCENIV production.
  • Strong ASCENIV demand and expansion in payer coverage expected.
  • 2026 total revenue guidance increased to approximately $635 million.
  • ADMA targets over $1.1 billion in annual revenue by FY 2029.

Companies Mentioned

  • BIIB (BIIB)
  • INTC (INTC)
  • ABBV (ABBV)

Corporate Developments

ADMA's promising revenue growth and strategic initiatives directly impact investor confidence and stock performance.

ADMA Biologics Reports Strong Preliminary Revenue for FY 2025 and Strategic Updates

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 12, 2026 — ADMA Biologics, Inc. (Nasdaq: ADMA) announces its preliminary unaudited total revenue for the fiscal year 2025, projected at approximately $510-$511 million. This figure meets or exceeds previous guidance, marking a significant milestone in the company's financial trajectory.

Financial Performance Highlights

ADMA’s financial results for FY 2025 show a year-end available cash balance of around $88 million, which includes an estimated operating cash flow of approximately $40 million for the fourth quarter. The company has reiterated its adjusted EBITDA and adjusted net income guidance for FY 2025.

Future Revenue Forecasts

  • FY 2026 revenue is projected at approximately $635 million, up from $630 million.
  • FY 2027 revenue is expected to reach approximately $775 million.
  • Adjusted net income for FY 2026 and FY 2027 is targeted at $255 million and $315 million, respectively.
  • Adjusted EBITDA forecasts for FY 2026 and FY 2027 stand at $360 million and $455 million, respectively.
  • ADMA aims to achieve over $1.1 billion in annual revenue by FY 2029, with more than $700 million in adjusted EBITDA.

Strategic Operational Updates

ADMA is poised for significant operational advancements in 2026, marked as the company’s first full year of yield-enhanced production. This development is critical for supporting anticipated margin expansions.

Plasma Network Repositioning

The strategic repositioning of ADMA's plasma collection network is expected to further enhance profit margins and long-term supply visibility. In December 2025, ADMA finalized a deal to divest three plasma centers for approximately $12 million. This action reinforces the company’s commitment to a more flexible and capital-efficient supply model.

Product Demand and Clinical Outcomes

Demand for ADMA’s flagship product, ASCENIV™, has accelerated due to its clinical differentiation and strong payer coverage. A statistically significant reduction in infection rates has been demonstrated in studies involving ASCENIV, further validating its value.

Clinical Data Highlights

  • 71% of patients showed clinical improvement after using ASCENIV, particularly within the first six months of treatment.
  • Independent studies reinforce ASCENIV's efficacy, particularly in patients with recurrent respiratory infections.

Looking Ahead: Growth and Stockholder Value

“We are pleased with our performance in 2025 and the strong exit momentum we are carrying into 2026,” stated Adam Grossman, President and CEO of ADMA. He emphasized confidence in long-term plasma supply, streamlined operations, and increasing visibility across demand and production.

Conclusion

ADMA Biologics is committed to accelerating growth while enhancing stockholder value. As they prepare for substantial revenue increases and operational efficiencies, stakeholders can expect robust engagement and continued innovation throughout 2026 and beyond.

Related News